JBI-802 Drug Asset Due Diligence Report 2026

This JBI-802 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether JBI-802 can convert its Small molecule drug profile and HDAC6 x KDM1A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	JBI-802 (query alias: JBI-802)
Modality / target	Small molecule drug; HDAC6 x KDM1A; HDAC6 inhibitors, KDM1A inhibitors, Epigenetic drug
Highest global status	Phase 2
Originator	Jubilant Therapeutics, Inc.
Active developers	Jubilant Therapeutics, Inc., The Christ Hospital

The MCP disease footprint includes Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Myelodysplastic-Myeloproliferative Diseases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07612280	Phase 1/2	Recruiting	30	Primary endpoint not disclosed in English source
NCT07207395	Phase 2	Recruiting	30	Primary endpoint not disclosed in English source
NCT05268666	Phase 1/2	Unknown status	126	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Anti-tumor activity of CoREST inhibitor, JBI-802 (dual epigenetic modifier of LSD1/HDAC6): An opportunity to treat essential thrombocythemia and MPN/MDS patients with thrombocytosis in ongoing phase 1/2 clinical trial.

Phase 1/2; n=30; evaluation: Positive. Reported fields: PR = confirmed partial response (PR) in one NSCLC patient at 10 mg dose

JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis

Phase 1; n=11; evaluation: Positive. Reported fields: AE = Platelet decrease is the only adverse event above grade 1 observed in these patients, no AEs (Adverse Events) of anemia has been observed, which is potentially due to the positive benefit of inhibition of HDAC6 in erythrocytes. Also, there are no reports of Dysgeusia, an adverse event that has been observed with LSD1-only inhibitors. ; AE = Platelet decrease is the only adverse event above grade 1 observed in these patients, no AEs (Adverse Events) of anemia has been observed, which is potentially due to the positive benefit of inhibition of HDAC6 in erythrocytes. Also, there are no reports of Dysgeusia, an adverse event that has been observed with LSD1-only inhibitors.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

JBI-802 addresses Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Myelodysplastic-Myeloproliferative Diseases. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 10 matched transaction record(s) under the scope “target-level comparable: HDAC6 x KDM1A.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HDAC6 x KDM1A records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2023-11-07	Novartis Secures $1.3 Billion Deal with Chong Kun Dang for HDAC6 Inhibitor Targeting CMT Disease	Phase 1	US$80.0M upfront; US$1,230.0M milestones
2023-03-22	Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates	Preclinical	Financial terms not disclosed
2022-07-29	The basque-based company Quimatryx licenses a cancer drug for 92 million dollars	Phase 1	US$92.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Dual LSD1/HDAC inhibitors”. The milestone feed surfaced a patent-application signal described as “Dual LSD1/HDAC inhibitors”. The milestone feed surfaced a patent-application signal described as “Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO